Regenerating Tomorrow
Starting Today
Cutting-edge autologous solution for wound healing, aesthetics and dermatology
Important Regulatory Disclaimers!
The FastSkin® Treatment has not yet received regulatory approval in the U.S. and Canada. As such, use is limited to investigational use only in the U.S. Any statement about the safety and effectiveness of the system does not apply to the U.S. and Canada because the treatment is currently undergoing clinical investigation in these geographies.
At mimiX AWC*, our mission is to enhance wound care by combining our advanced Sound Induced Morphogenesis technology with the body’s natural healing processes. We are dedicated to improving the lives of those with complex wounds through innovative solutions and compassionate, science-driven care.
*mimiX AWC is a sister company of Mimix Biotherapeutics Ltd.
FastSkin®
At the forefront of wound care innovation, we offer a unique approach designed to support the natural healing process using your body’s own resources. Our treatment utilizes a minimally invasive technique that leverages your own blood and skin cells to help manage chronic wounds such as diabetic foot ulcers, venous and pressure ulcers, and surgical wounds.
How it Works
This treatment leverages the patient’s autologous blood and micro-tissues, processed using a proprietary acoustic biofabrication technology to generate a personalized wound care matrix. The approach is designed to stimulate the body’s intrinsic repair mechanisms while avoiding the risks associated with synthetic or allogenic materials. The workflow is streamlined for clinical settings, enabling point-of-care application with minimal manipulation.
Why It’s Different
Unlike conventional treatments that depend on synthetic or donor-derived (allogenic) materials, our approach is rooted in autologous care, utilizing the patient’s own biological materials. This reduces immunological risks, enhances biocompatibility, and supports more natural tissue regeneration. Though still undergoing clinical evaluation, this method marks a meaningful step toward safer, more personalized, and biologically aligned care.
Autologous Cell Therapy Portfolio
for Advanced Wound Management
FastSkin® – An Integrated Treatment Ecosystem to Improve the Healing Experience. Our innovative platform is built around a modular suite of solutions, each designed to enhance and complement the regenerative process from day one, offering a more efficient and patient-centered healing experience.
FastSkin® Patch
Bioactive Matrix
Created at the point-of-care from autologous material, FastSkin® is a biological patch containing the patient’s own regenerative cocktail, designed to support tissue repair and improve the healing experience.
Tissue Mincer
Autologous Micrografting Solution
Transforms the patient's own tissue into full-thickness micrografts for personalized healing.
Symphony
The Sound Centrifuge
Activates the biological matrix through sound-induced morphogenesis (SIM) for enhanced regeneration.
Chronic Wounds
The increasing prevalence of diabetes and population aging are key drivers behind the growing burden of chronic, non-healing wounds on healthcare systems.
Chronic cutaneous ulcers are wounds that fail to progress through the normal stages of healing in a timely and organized way, ultimately preventing stable structural, functional, and aesthetic closure. Delayed healing is often linked to underlying macrovascular and microvascular disorders, which impair blood flow and tissue regeneration.
Chronic leg ulcers affect approximately 1% of the population, including those caused by venous, arterial, or mixed vascular issues. Source
Diabetic foot ulcers, a common complication of diabetes, impact up to 25% of people living with the disease over their lifetime.
Source
Innovation Roadmap
From Repair to Regeneration: A Staged Roadmap Transforming Skin Care, from Chronic Wounds Management to Aesthetic Applications.
STAGE 1
$5.7bn
Chronic Wound
Opportunities
Diabetic Foot Ulcers (DFUs, Venous & Pressure ulcers, Surgical Wounds
Key Growth Drivers
Diabetes, Malnutrition, demographic trend
STAGE 2
$34bn
Dermatology
Opportunities
Scare Treatment, regeneration and anti-aging therapies
Key Growth Drivers
Rising demand for innovative treatments for scars, keloids and skin degeneration due to aging
STAGE 3
$87bn
Aesthetics
Opportunities
Expanding SIM Technology applications for skin rejuvenation, post-procedure recovery and hair regeneration
Key Growth Drivers
Growing global interest in minimaly invasive cosmetic treatment and the anti-aging sector
Structuring Blood for Regeneration
Fig1: Blood cells patterned, in circles (left), in lines (right)
Fig2: Blood cells unpatterned (left), patterned (right)
Red Blood cells
Boosting Oxygen Delivery - SIM arranges RBCs into optimized configurations, improving oxygen diffusion to the wound site, a critical factor in tissue repair regeneration
White Blood cells
Enhancing Immune Response by organizing white blood cells spatially, SIM enhances immune surveillance, reduces infoction risk, and supports faster resolution of inflammation.
Platelets
Enhancing Regeneration by forming stable clots and releasing growth factors more efficiently, smoothing tissue recovery..
Accelerating Healing with Micrografts
Chronic wounds often resist conventional treatments due to poor blood flow, infection, and stalled regeneration. Micrograft technology changes the game by reintroducing the body’s own regenerative power directly into the wound.
Why Micrografts?
Each individual micrograft (200-400µm) is a living piece of skin tissue equipped with a pre-vascularized system that “kicks” the local surrounding tissue – regeneration.
The cells contained in the micrografts, proliferate out and populate the surrounding extracellular matrix.
Encapsulated at grafting time in the blood clot, they access nutrients, platelets and proteins supporting the wound bed remodeling.
Processed blood patch turbo-charged with skin micrografts